TLX fell -9.85% to about $11.35 during Monday's regular session, down from a prior close of $12.59. The drop followed Telix's $1.65 billion upfront merger agreement with privately held German radioisotope producer ITM Isotope Technologies Munich.

KPLT fell about -10.53% during regular trading Monday, sliding from a $9.50 prior close to roughly $8.50. The move reverses Friday's +3.37% gain and a heavy-volume spike, after a ~+60% one-month surge following its August all-stock merger with The Aaron's Company and CCF Holdings.

PBLS fell -11.84% to $36.79 during regular trading Monday, down from Friday's $41.73 close. The drop came amid a broad biotech and pharmaceutical selloff, with PBLS among the session's biggest sector losers.

BRVE is down -14.32% to $25.02 during Monday's regular session, off Friday's $29.20 close, on heavy volume (~1.0M shares vs ~464K average). The slide extends a post-earnings selloff after Sept 8 Q2 results showed a far wider loss (diluted EPS -$2.51 vs -$0.25 consensus) with zero revenue.

APMD fell -12.66% during regular trading, retreating to roughly $25.33 from Friday's $29.00 close. The decline follows Friday's +3.17% surge on ~3.1M shares—well above its ~531K average—leaving the newly public biotech prone to profit-taking.

EMAT is trading down -16.42% to roughly $3.36 during regular market hours, sliding from Friday's close of $4.02. The decline follows a Yorkville financing deal of up to $30.93M in convertible debentures, including an immediate $22M tranche.

Magnachip Semiconductor (MX) climbed +16.36% to roughly $3.20 during regular trading, extending gains that began premarket. The move was driven by Navitas Semiconductor's announcement of a $5 million strategic equity investment, buying ~1.46 million Magnachip shares at $3.42 each.

REFR is down roughly -14% intraday, trading near $0.56 after closing at $0.6513 on Friday, September 18. The decline is occurring during regular market hours on Monday, September 21, as the stock pulls back from Friday's surge.

General Dynamics shares declined roughly 8% over the trailing 30 days, from a closing price near $384.29 to a most recent close of $353.05, even as underlying fundamentals remained strong. The pullback largely reflected sector-wide profit-taking and rising-rate concerns rather than deterioration in the company's operating results.

Critical Metals Corp. (CRML) focuses on lithium and rare earth elements with projects in Austria and Greenland, while NioCorp Developments Ltd. (NB) targets niobium, scandium, and titanium at its Elk Creek project in Nebraska. Both companies operate in the critical minerals sector, exposing them to similar macroeconomic drivers such as electrification demand and supply chain diversification.

RDCM has held near the $10 level over the past 30 days, roughly flat after a sharp July selloff triggered by a cut to full-year revenue guidance. Second-quarter 2026 revenue declined 33.4% year over year to $11.8 million as customer deployments were delayed by component-cost and supply constraints.

Both CRML and USAR operate in the critical minerals and rare earths sector, with exposure to lithium, heavy rare earth elements, and materials essential for electrification and defense applications. Recent market activity shows elevated volatility for both stocks, driven by project updates and sector-wide interest in domestic supply chains amid global competition for rare earth processing.

The selected price objective is $8.00 , roughly 40% above recent trading levels and well beyond the stock's 52-week high of approximately $6.25. The strongest bullish case rests on a growing defense backlog, including work tied to the U.S. Navy submarine program, and recovering revenue momentum.

NVOX, the 2x leveraged long Novo Nordisk ADR ETF, fell -16.20% to about $10.40 during Monday's regular session, roughly doubling the underlying NVO's ~-7% slide. The primary catalyst: Novo Nordisk's Capital Markets Day targets underwhelmed, reiterating a ~$23 billion obesity/pipeline sales goal rather than raising it, while guiding 2026–30 revenue growth only in line with peers.

QNME is trading down about -10.34% during Monday's regular session, near $0.50, versus Friday's $0.5583 close. The pullback is a giveback of Friday's +92.25% spike, when shares surged to $0.5583 (intraday high $1.03) on roughly 328M shares with multiple volatility trading halts.

RKLZ is down -13.47% intraday during regular market hours, sliding from $19.08 to $16.51. The move is mechanical: RKLZ is a 2x inverse ETF, so it falls when underlying Rocket Lab (RKLB) rallies.

MSTZ fell -15.25% to $2.39, down -$0.43 from Friday's $2.82 close, sliding in premarket and extending the loss into the regular session. As a -2x daily inverse of MicroStrategy (MSTR), MSTZ moves opposite MSTR; MSTR jumped about +7.4% premarket, mechanically pressuring the ETF.

DAMD is down -17.92% today, falling from a prior close of $11.05 to roughly $9.07 during the regular trading session. The decline is driven by a sharp rally in its underlying reference asset, AMD, which surged to record highs and pushed its market cap toward $1 trillion.

AXTQ fell -32.37% intraday during regular market hours, dropping from $32.56 to about $22.02. The drop is mechanical: AXTQ is a -2x daily inverse ETF that moves opposite to AXT Inc. (AXTI), so it slides when AXTI rallies.

CUE is down -27.45% in the regular session, trading near $26.88 versus Friday's close of $37.05. The stock initially spiked roughly +41% premarket after positive Phase 2 CUE-221 results in chronic spontaneous urticaria (primary and key secondary endpoints met).